Half-Life of Albumin and Its Clinical Implications

Physiological Context

• The half-life of albumin is approximately 20 days in healthy individuals, according to the American Journal of Kidney Diseases 1
• The turnover of human serum albumin has a half-life ranging from 14-20 days, making albumin-based glycation markers more sensitive to short-term changes in glycemic control, as noted by Diabetes Care 2, 3

Clinical Implications

For Glycemic Monitoring

• Glycated albumin (GA) reflects glycemic control over approximately 2-3 weeks, specifically the preceding 1-2 weeks for a single measurement, as reported by Diabetes Care and Diabetes/Metabolism Research and Reviews 2, 3, 4, 5
• Conditions affecting albumin turnover will alter GA levels independent of glucose control, such as accelerated turnover in hyperthyroidism, obesity, or nephrotic syndrome, which falsely lowers GA, and decreased turnover in hypothyroidism or liver cirrhosis, which falsely elevates GA, according to Diabetes/Metabolism Research and Reviews 4, 5

For Nutritional Assessment

• Prealbumin has an even shorter half-life of 2-3 days versus albumin's 20 days, making it theoretically more sensitive to acute nutritional changes, as noted by the American Journal of Kidney Diseases 1
• Serum transferrin has an intermediate half-life of 8 days, but its utility is compromised by iron status effects, making it less clinically useful than albumin in dialysis populations, as reported by the American Journal of Kidney Diseases 6